NCT04516447 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04516447
Title	A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (MUIR)
Acronym	MUIR
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Indications	ovarian serous carcinoma peritoneal carcinoma endometrioid ovary carcinoma fallopian tube carcinoma
Therapies	Azenosertib + Gemcitabine Azenosertib + Paclitaxel Azenosertib + Pegylated liposomal doxorubicin Azenosertib + Bevacizumab Azenosertib + Carboplatin
Age Groups:	adult \| senior
Covered Countries	USA \| BGR \| AUS

NCT04516447
Clinical Trial Detail